Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.810 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Lineage Cell Revenue Doubles in Q2
Via The Motley Fool
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027. 
Via Chartmill
A Peek at Lineage Cell Therapeutics's Future Earnings
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock
 
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
Two Biotech Stocks Poised For Big Moves On Monday
 
Via Benzinga
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook
 
Via Benzinga
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts
 
Via Benzinga
Lineage Cell Therapeutics's Earnings Outlook
 
Via Benzinga
Lineage Cell Therapeutics: Q4 Earnings Insights
 
Via Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For March 10, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For November 14, 2024
 
Via Benzinga
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.